EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pyrazolo[1,5-a]pyrimidine scaffold-based small molecules: From bench to FDA-approved TRK kinase inhibitors (Part 1)

Mustafa A Al-Qadhi, Tawfeek A A Yahya, Anas A Alqadhi, Reem K Arafa

European Journal of Medicinal Chemistry · 2026

DOI: 10.1016/j.ejmech.2025.118348 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Medicinal Chemistry, 2026. Verfasst von Mustafa A Al-Qadhi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, P.O. Box 18084, Sana'a, Yemen. Electronic address: mustafa.alqadhi@std.pha…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Pyrimidines, Pyrazoles, Small Molecule Libraries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 112 Literaturangaben. Gefördert von: U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pyrazolo[1,5-a]pyrimidine scaffold has emerged as a privileged structure in medicinal chemistry, particularly in designing kinase-targeted therapeutics, such as tropomyosin receptor kinase (TRK) inhibitors, for targeted cancer therapy. This review provides a critical analysis of small molecules bearing this heterocyclic motif, focusing on their chemical evolution, structure-activity relationship (SAR)- driven optimization, mechanistic insights into TRK inhibition, and the translational journey of these compounds from preclinical studies to FDA-approved drugs, such as Larotrectinib. The review highlights the strategic chemical modifications that improved selectivity, pharmacokinetics, and safety profiles of TRK inhibitors. Additionally, it outlines the evolution of kinase inhibitor design strategies leveraging this scaffold and discusses current challenges and future directions in optimizing these compounds for broader clinical applications. This work aims to serve as a foundation for ongoing drug discovery efforts utilizing the pyrazolo[1,5-a]pyrimidine core in oncogenic kinase targeting. Collectively, this work underscores the significance of the pyrazolo[1,5-a]pyrimidine scaffold as a privileged chemotype and sets the stage for the rational development of next-generation TRK inhibitors with enhanced clinical utility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsPyrimidinesPyrazolesSmall Molecule LibrariesAntineoplastic AgentsReceptor, trkAHumansStructure-Activity RelationshipUnited StatesMolecular StructureUnited States Food and Drug AdministrationAnimalsDrug Approval

Stichwörter der Autor:innen

Drug designFDAPyrazolo[1,5-a]pyrimidineSARTRK inhibitors

Substanzen

Protein Kinase InhibitorsPyrimidinesPyrazolesSmall Molecule Librariespyrazolo(1,5-a)pyrimidineAntineoplastic AgentsReceptor, trkA

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, P.O. Box 18084, Sana'a, Yemen. Electronic address: mustafa.alqadhi@std.pharma.cu.edu.eg.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, Sana'a University, P.O. Box 18084, Sana'a, Yemen.
  • Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Sana'a University, P.O. Box 18084, Sana'a, Yemen.
  • Drug Design and Discovery Laboratory, Zewail City of Science and Technology, October Gardens, 6th of October City, 12578, Giza, Egypt; Biomedical Sciences Program, UST, Zewail City of Science and Technology, October Gar…

Förderung

  • U.S. Food and Drug Administration

Zitieren

APA

Al-Qadhi, M. A., Yahya, T. A. A., Alqadhi, A. A., & Arafa, R. K. (2026). Pyrazolo[1,5-a]pyrimidine scaffold-based small molecules: From bench to FDA-approved TRK kinase inhibitors (Part 1). European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2025.118348

Vancouver

Al-Qadhi MA, Yahya TAA, Alqadhi AA, Arafa RK. Pyrazolo[1,5-a]pyrimidine scaffold-based small molecules: From bench to FDA-approved TRK kinase inhibitors (Part 1). European Journal of Medicinal Chemistry. 2026. doi:10.1016/j.ejmech.2025.118348

BibTeX
@article{AlQadhi2026,
  author = {Al-Qadhi, Mustafa A and Yahya, Tawfeek A A and Alqadhi, Anas A and Arafa, Reem K},
  title = {Pyrazolo[1,5-a]pyrimidine scaffold-based small molecules: From bench to FDA-approved TRK kinase inhibitors (Part 1)},
  journal = {European Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1016/j.ejmech.2025.118348}
}
Kostenlos starten →